These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23942260)

  • 1. Current challenges and opportunities in nonclinical safety testing of biologics.
    Kronenberg S; Baumann A; de Haan L; Hinton HJ; Moggs J; Theil FP; Wakefield I; Singer T
    Drug Discov Today; 2013 Dec; 18(23-24):1138-43. PubMed ID: 23942260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new Insights.
    Blaich G; Baumann A; Kronenberg S; de Haan L; Ulrich P; Richter WF; Tibbitts J; Chivers S; Tarcsa E; Caldwell R; Crameri F
    Regul Toxicol Pharmacol; 2016 Oct; 80S():S1-S14. PubMed ID: 27578450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New challenges and opportunities in nonclinical safety testing of biologics.
    Baumann A; Flagella K; Forster R; de Haan L; Kronenberg S; Locher M; Richter WF; Theil FP; Todd M
    Regul Toxicol Pharmacol; 2014 Jul; 69(2):226-33. PubMed ID: 24755365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing.
    Ulrich P; Blaich G; Baumann A; Fagg R; Hey A; Kiessling A; Kronenberg S; Lindecrona RH; Mohl S; Richter WF; Tibbitts J; Crameri F; Weir L
    Regul Toxicol Pharmacol; 2018 Apr; 94():91-100. PubMed ID: 29355662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonclinical Development of Biologics: Integrating Safety, Pharmacokinetics, and Pharmacodynamics to Create Smarter and More Flexible Nonclinical Safety Programs Optimizing Animal Use.
    Hey A; Baumann A; Kronenberg S; Blaich G; Mohl S; Fagg R; Ulrich P; Rattel B; Richter WF; Kiessling A; Weir L
    Int J Toxicol; 2021; 40(3):270-284. PubMed ID: 33631988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting.
    Kissner T; Blaich G; Baumann A; Kronenberg S; Hey A; Kiessling A; Schmitt PM; Driessen W; Carrez C; Kramer D; Fretland J; Richter WF; Paehler T; Hopfer U; Rattel B
    MAbs; 2021; 13(1):1938796. PubMed ID: 34241561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapies.
    Brennan FR; Baumann A; Blaich G; de Haan L; Fagg R; Kiessling A; Kronenberg S; Locher M; Milton M; Tibbitts J; Ulrich P; Weir L
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):265-75. PubMed ID: 26219199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of biological therapies for neurological diseases: moving on from previous failures.
    Qosa H; Volpe DA
    Expert Opin Drug Discov; 2018 Apr; 13(4):283-293. PubMed ID: 29394876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.
    Everds NE; Tarrant JM
    Toxicol Pathol; 2013 Feb; 41(2):280-302. PubMed ID: 23471185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the future of PEGylated therapies?
    Swierczewska M; Lee KC; Lee S
    Expert Opin Emerg Drugs; 2015; 20(4):531-6. PubMed ID: 26583759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies.
    MacLachlan TK; Kronenberg S; Marshall N; Andrews L; Berens SJ; Brouta F; Fogal B; Freebern W; Herzyk D; Kamperschroer C; Kiessling A; Schneidkraut M; Maier C
    Regul Toxicol Pharmacol; 2021 Feb; 119():104825. PubMed ID: 33220389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylated biologics in haemophilia treatment: Current understanding of their long-term safety.
    Baumann A
    Haemophilia; 2020 Jan; 26(1):e11-e13. PubMed ID: 31742794
    [No Abstract]   [Full Text] [Related]  

  • 15. Biologic therapy with or without topical treatment in psoriasis: what does the current evidence say?
    Jensen JD; Delcambre MR; Nguyen G; Sami N
    Am J Clin Dermatol; 2014 Oct; 15(5):379-85. PubMed ID: 25027461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathological Findings in Cynomolgus Macaques ( Macaca fascicularis) Consistent with Secondary Immunological Reaction to Biotherapeutics with an Emphasis on the CNS and Eye.
    Naylor SW; Czajkowski M; Harvey W; Smith M; Bradley AE; Cary M
    Toxicol Pathol; 2019 Feb; 47(2):165-173. PubMed ID: 30636523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.
    Namdari R; Jones K; Chuang SS; Van Cruchten S; Dincer Z; Downes N; Mikkelsen LF; Harding J; Jäckel S; Jacobsen B; Kinyamu-Akunda J; Lortie A; Mhedhbi S; Mohr S; Schmitt MW; Prior H
    Regul Toxicol Pharmacol; 2021 Nov; 126():105029. PubMed ID: 34455009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
    Ivens IA; Achanzar W; Baumann A; Brändli-Baiocco A; Cavagnaro J; Dempster M; Depelchin BO; Rovira AR; Dill-Morton L; Lane JH; Reipert BM; Salcedo T; Schweighardt B; Tsuruda LS; Turecek PL; Sims J
    Toxicol Pathol; 2015 Oct; 43(7):959-83. PubMed ID: 26239651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of a Plug-and-Play Immunogenicity Assay in Cynomolgus Monkey Serum for ADCs at Early Stages of Drug Development.
    Carrasco-Triguero M; Davis H; Zhu Y; Coleman D; Nazzal D; Vu P; Kaur S
    J Immunol Res; 2016; 2016():2618575. PubMed ID: 27092313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.